open access

Vol 9, No 2 (2003)
Review papers
Published online: 2003-03-25
Get Citation

Endothelial progenitor cells (EPCs) in therapy

Łukasz Partyka, Krzysztof Siwiec, Rafał Niżankowski, Tomasz Petriczek, Antoni Basta, Aleksander B. Skotnicki, Aldona Dembińska-Kieć
Acta Angiologica 2003;9(2):53-62.

open access

Vol 9, No 2 (2003)
Review papers
Published online: 2003-03-25

Abstract

Stem progenitor cells serve as a functional reserve and may differentiate into mature cells with a different phenotype. Partially differentiated endothelial progenitor cells (EPCs) are characterized by the expression of surface molecules such as endoglin (CD105), vWF, PECAM-1/CD31, VE-cadherin, CD146, CD62E, CD51/61, CD106, CD41a, CD41b, CD34 and AC133, growth factor receptors (e.g. Flt-1, KDR and Tie-1) and others. They may also express the functional capabilities of endothelial cells in the course of their differentiation (e.g. incorporation of modified LDL). Animal studies have confirmed the proangiogenic activity of labelled human (bone marrow, umbilical cord and peripheral blood) as well as animal EPCs in the experimental models of myocardial, peripheral and cerebral ischaemia. The goal of these studies has been to improve the vascularisation and functional activity of the target organs.
The first clinical studies in peripheral and coronary artery disease revealed the clinical efficacy of human bone marrow-derived mononuclear fraction in diminishing the adverse effects of peripheral and myocardial ischaemia. No significant side-effects of the EPC application were observed, but further studies are required to confirm the long-term safety and efficacy of this method as well as to assess its possible hazards.

Abstract

Stem progenitor cells serve as a functional reserve and may differentiate into mature cells with a different phenotype. Partially differentiated endothelial progenitor cells (EPCs) are characterized by the expression of surface molecules such as endoglin (CD105), vWF, PECAM-1/CD31, VE-cadherin, CD146, CD62E, CD51/61, CD106, CD41a, CD41b, CD34 and AC133, growth factor receptors (e.g. Flt-1, KDR and Tie-1) and others. They may also express the functional capabilities of endothelial cells in the course of their differentiation (e.g. incorporation of modified LDL). Animal studies have confirmed the proangiogenic activity of labelled human (bone marrow, umbilical cord and peripheral blood) as well as animal EPCs in the experimental models of myocardial, peripheral and cerebral ischaemia. The goal of these studies has been to improve the vascularisation and functional activity of the target organs.
The first clinical studies in peripheral and coronary artery disease revealed the clinical efficacy of human bone marrow-derived mononuclear fraction in diminishing the adverse effects of peripheral and myocardial ischaemia. No significant side-effects of the EPC application were observed, but further studies are required to confirm the long-term safety and efficacy of this method as well as to assess its possible hazards.
Get Citation

Keywords

endothelial progenitor cells; angiogenesis; tissue ischaemia

About this article
Title

Endothelial progenitor cells (EPCs) in therapy

Journal

Acta Angiologica

Issue

Vol 9, No 2 (2003)

Pages

53-62

Published online

2003-03-25

Bibliographic record

Acta Angiologica 2003;9(2):53-62.

Keywords

endothelial progenitor cells
angiogenesis
tissue ischaemia

Authors

Łukasz Partyka
Krzysztof Siwiec
Rafał Niżankowski
Tomasz Petriczek
Antoni Basta
Aleksander B. Skotnicki
Aldona Dembińska-Kieć

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl